Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Demyelinating disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    79 result(s) found for: Demyelinating disease. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2013-004157-24 Sponsor Protocol Number: IgPro20_3004 Start Date*: 2014-04-30
    Sponsor Name:CSL Behring GmbH
    Full Title: Multicenter, open-label extension study to investigate the long-term safety and efficacy of IgPro20 in maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in subjec...
    Medical condition: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10061811 Demyelinating polyneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) DE (Completed) ES (Completed) FI (Completed) NL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-003448-28 Sponsor Protocol Number: IgPro20_3003 Start Date*: 2012-04-20
    Sponsor Name:CSL Behring GmbH
    Full Title: Randomized, multicenter, double-blind, placebo-controlled, parallel-group phase III study to investigate the efficacy, safety, and tolerability of 2 different doses of IgPro20 (subcutaneous immunog...
    Medical condition: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10061811 Demyelinating polyneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) ES (Completed) FI (Completed) NL (Completed) AT (Completed) GB (Completed) IT (Completed) BE (Completed) LT (Prematurely Ended) PL (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004392-12 Sponsor Protocol Number: CIDP04 Start Date*: 2019-11-20
    Sponsor Name:UCB Biopharma SPRL
    Full Title: An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
    Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) BE (Completed) ES (Restarted) NL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-017672-24 Sponsor Protocol Number: IgPro10_3001 Start Date*: 2010-09-13
    Sponsor Name:CSL Behring GmbH
    Full Title: A single-arm study to demonstrate the efficacy and safety of Privigen in the treatment of subjects with chronic inflammatory demyelinating polyneuropathy (CIDP)
    Medical condition: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10061811 Demyelinating polyneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2016-002411-17 Sponsor Protocol Number: CIDP01 Start Date*: 2019-04-29
    Sponsor Name:UCB Biopharma SRL
    Full Title: A Multicenter, Randomized, Subject-Blind, Investigator-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Rozanolixizumab in Subjects with Chronic ...
    Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DK (Completed) NL (Completed) DE (Completed) ES (Completed) FR (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-005034-36 Sponsor Protocol Number: CIDPRIT Start Date*: 2018-05-22
    Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS
    Full Title: An Italian database-based randomized controlled trial with Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
    Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10072650 CIDP LLT
    21.1 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    21.1 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005558-31 Sponsor Protocol Number: I10E-1306 Start Date*: 2015-01-08
    Sponsor Name:LFB BIOTECHNOLOGIES
    Full Title: International, multicentre, efficacy and safety study of I10E in the maintenance treatment of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Extension of PRISM study I1...
    Medical condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Completed) IT (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-005557-73 Sponsor Protocol Number: I10E-1302 Start Date*: 2014-10-21
    Sponsor Name:LFB BIOTECHNOLOGIES
    Full Title: An international, multicentre, efficacy and safety study of I10E in initial and maintenance treatment of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy
    Medical condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001136-76 Sponsor Protocol Number: KB034Emendamenton°2 Start Date*: 2007-07-09
    Sponsor Name:KEDRION
    Full Title: Double blind Randomized Controlled trial of prolonged treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)with high dose intravenous immunoglobulins (IVIg) or intravenous m...
    Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002438-34 Sponsor Protocol Number: FAM1 Start Date*: 2020-08-19
    Sponsor Name:Department of Neurology, Odense University Hospital
    Full Title: Fampridine for treatment of residual neurological deficits in patients treated with immunoglobulins for chronic inflammatory demyelinating polyneuropathy
    Medical condition: Chronic inflammatory demyelinating polyneuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10072650 CIDP LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001347-31 Sponsor Protocol Number: RF-2016-02361887 Start Date*: 2018-07-30
    Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS
    Full Title: Anti-nerve reactivity as predictor of response to immune therapy in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): A proof of concept study with rituximab in patie...
    Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10072650 CIDP LLT
    21.1 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005280-24 Sponsor Protocol Number: CFTY720I2201 Start Date*: 2012-10-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double-blind, randomized, multicenter, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 0.5 mg fingolimod administered orally once daily versus placebo in patients ...
    Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) DE (Prematurely Ended) ES (Completed) GB (Prematurely Ended) IT (Completed) GR (Completed) PL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-013930-25 Sponsor Protocol Number: 2009-600 Start Date*: 2009-11-24
    Sponsor Name:Aarhus University Hospital, Department of Neurology
    Full Title: Randomiseret, dobbelt blindet placebokontrolleret undersøgelse af subkutan immunglobulinbehandling af kronisk inflammatorisk demyeliniserende polyradikuloneuropati (English: A randomized, double-...
    Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy
    Disease: Version SOC Term Classification Code Term Level
    12.0 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006392-21 Sponsor Protocol Number: P050801 Start Date*: 2007-11-20
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Etude des effets des immunoglobulines intraveineuses sur l'excitabilité nerveuse dans les neuropathies démyélinisantes dysimmunes chroniques
    Medical condition: Patients suivis dans le service de Neurologie de l'Hôpital Henri Mondor pour une neuropathie démyélisante dysimmunes chroniques. Patients nécessitant un traitement par immunoglobulines intraveineus...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001996-34 Sponsor Protocol Number: IGNG-0904 Start Date*: 2013-07-10
    Sponsor Name:LFB BIOTECHNOLOGIES
    Full Title: A comparative, double-blind, randomised, multicentre efficacy and safety study of ClairYg® versus Tégéline® in maintenance treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
    Medical condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-017805-13 Sponsor Protocol Number: NGAM-03 Start Date*: 2011-07-14
    Sponsor Name:Octapharma AG
    Full Title: "PROSPECTIVE, PARALLEL GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTICENTER, ADAPTIVE, TWO-STAGE PHASE II/III STUDY EVALUATING SAFETY AND EFFICACY OF THREE DIFFERENT DOSAGES OF NEWGAM I...
    Medical condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) RO (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002968-49 Sponsor Protocol Number: BN43118 Start Date*: 2022-06-24
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN PATIENTS WITH GUILLAIN-BARRÉ S...
    Medical condition: Guillain-Barré syndrome (GBS)
    Disease: Version SOC Term Classification Code Term Level
    22.1 10029205 - Nervous system disorders 10018767 Guillain-Barre syndrome PT
    21.1 10029205 - Nervous system disorders 10018766 Guillain Barre syndrome LLT
    21.1 10029205 - Nervous system disorders 10042812 Syndrome Guillain-Barre LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005659-83 Sponsor Protocol Number: SID2009 Start Date*: 2010-01-28
    Sponsor Name:Erasmus MC
    Full Title: Second IVIg Dose in GBS patients with poor prognosis (SID-GBS trial)
    Medical condition: Guillian-Barre syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10018767 Guillain-Barre syndrome PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001150-15 Sponsor Protocol Number: MD1003CT2015-01-SERENDEM Start Date*: 2016-03-14
    Sponsor Name:MEDDAY PHARMACEUTICALS
    Full Title: SERENDEM study: MD1003 in patients suffering from demyelinating neuropathies, an open label pilot study
    Medical condition: chronic inflammatory demyelinating polyradiculoneuropathy, demyelinating neuropathy associated with immunoglobulin M (IgM) monoclonal gammopathy and antibodies against myelin-associated glycoprotei...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10066137 Anti-MAG neuropathy LLT
    18.1 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    18.1 100000004850 10008414 Charcot-Marie-Tooth disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-000374-37 Sponsor Protocol Number: 161505 Start Date*: 2016-10-28
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculone...
    Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DK (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) NO (Completed) GR (Completed) SK (Prematurely Ended) DE (Completed) PL (Completed) HR (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 08:19:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA